Controversies in the therapy of acute myelogenous leukemia.
In the past 10 years, there has been substantial progress in the treatment of patients with acute myelogenous leukemia. Intensive induction chemotherapy and consolidation chemotherapy have increased complete remission rates from 25 percent to more than 70 percent and have extended median survival from six months to more than two years. Attempts to prolong remission with maintenance chemotherapy, immunotherapy, and central nervous system prophylaxis have been less successful. Recent data suggest that the use of intensification chemotherapy or bone marrow transplantation in patients in remission may further reduce or eliminate residual leukemia. As a result of one or more of these advances an increasing proportion of patients, up to 25 percent in some series, are alive and free of disease three to five years following diagnosis. Most data indicate that some of these patients may be cured. In this article, we review the therapeutic interventions responsible for this substantial increase in survival in what was previously a uniformly fatal disease. Recent advances are discussed as are controversies in management and future directions.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007239:Infections / Q000209:etiology / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents